BioCentury

12:29 AM GMT, Aug 28, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical News

T-DM1 meets OS endpoint

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said T-DM1 met the co-primary endpoint of improving overall survival vs. Tykerb lapatinib plus

Read the full 226 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.